Cellares' Cell Shuttle used in first patient infusions of Cabaletta Bio CAR T therapy
Source: SeekingAlpha
2026-04-15 02:14:31 ET
Read the full article on Seeking Alpha
For further details see:
Cellares’ Cell Shuttle used in first patient infusions of Cabaletta Bio CAR T therapy
Cabaletta Bio Inc.
NASDAQ: CABA
CABA Trading
-4.26% G/L:
$3.26 Last:
2,211,724 Volume:
$3.48 Open:
CABA Latest News
June 03, 2026 07:00:00 am
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
May 14, 2026 07:05:00 am
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
CABA Stock Data
$250,770,856
85,435,369
1.33%
21
N/A
Biotechnology & Life Sciences
Healthcare
US
Philadelphia
